Corixa, LigoCyte Pharmaceuticals deal

The companies will develop therapeutic and vaccine products that target Candida albicans infections using LigoCyte's anti-Candida antibodies. CRX will purchase LigoCyte equity, provide research funding and license fees and will be eligible for milestone payments and royalties. CRXA said that it may elect to market products based on the Candida technology either on its own or with a third party. ...